Pilot Study of the ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent

Trial Profile

Pilot Study of the ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms RESTORE
  • Sponsors REVA Medical
  • Most Recent Events

    • 26 Apr 2017 Planned End Date changed from 1 Sep 2018 to 1 Oct 2018.
    • 28 Jan 2014 Planned End Date changed from 1 Jul 2017 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
    • 21 May 2013 12-month results presented at the Paris Course on Revascularization (EuroPCR) according to a Reva media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top